SCHEMBL15095058

SCHEMBL15095058

Cn1c(=O)n(Cc2cccc(F)c2)c(=O)c2cc(C(=O)c3nc(-c4cccc(C(N)=O)c4)c4ccccn34)ccc21

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
MMP13 P45452 1/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
PARG Q86W56 3/20 0.39
POLB P06746 2/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAP3K14 Q99558 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322594 0.87 MMP13 (0.46) HDAC1HDAC11HDAC8HDAC6MMP13
SCHEMBL322222 0.85 HDAC1 (0.41) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL15094059 0.84 KDM4E (0.40) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL14916441 0.83 HDAC1 (0.44) HDAC1HDAC11HDAC8HDAC6MMP13
SCHEMBL321808 0.81 HDAC1 (0.39) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL14916111 0.81 PKM (0.44) HDAC1HDAC11HDAC8HDAC6MMP13
Hydrochloric Acid SCHEMBL322291 0.81 HDAC1 (0.39) MAPTHDAC1HDAC11HDAC8HDAC6
Hydrochloric Acid SCHEMBL14916909 0.81 PKM (0.44) HDAC1HDAC11HDAC8HDAC6MMP13
SCHEMBL322447 0.81 RORC (0.44) MMP13SLC22A8SMN1; SMN2ALDH1A1
SCHEMBL15093892 0.80 HDAC1 (0.39) MAPTHDAC1HDAC11HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US claimed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP claimed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US claimed
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US disclosed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US disclosed
EP-2800566-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2014-11-12 EP disclosed
WO-2013102860-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2013-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 MAPT 2290/4885HDAC1 248/4885HDAC11 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.